Esophageal Cancer

In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq (@NatureMedicine)

Congratulations @mdmanishshah & team on these GLOWing 💡💡🌟🌟 results & for so brightly changing the standard treatment for patients with #claudin18point2 #gastroesophageal #cancer ! #MedEd #MedX #MedTwitter (@drallysonocean)

The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)

“Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas” by Raisa Epistola, MD, Joseph Chao, MD, and Jennifer Lee, MD https://t.co/lPI7BsMr8o @JoeChaoMD @HarborUCLA @cityofhope (@clinadvances)

Featured today by @MSKLibrary: #SMARCA4 Mutations in #Carcinomas of the Esophagus, #Esophagogastric Junction, and Stomach: https://t.co/SRdw4D48zS @alexanderjneil @JamesClearyMD @feidng (@MSKLibrary)

Problem is, this is a routine FDA #CarteBlanche approval regardless of no benefit in PD-L1 1-49%. This will be Rx’d by everyone. Same for ICI in esophageal cancer- no benefit in CPS 1-4 but everyone with residual disease gets the adjuvant ICI, even if CPS 1 and frail. #CM577 (@jryckman3)

EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma @EMA_News #esocsm #oncology https://t.co/n9TlF3s5cv (@OncLive)

Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)

It's CAG #MemberMonday 🙌 Listen/download an exclusive accredited CAG Podcast episode 🔉 🎧 Ep. 49 - #ASCOGI2022 Post-Conference Podcast: Esophageal Cancer Highlights 👥 @GillSharlene @CTeshima 🔗 Log in now: https://t.co/fKLrRPjPzk (@CanGastroAssn)

New pub🚨: Survival and periop outcomes of pts aged >80 with resectable esophageal carcinoma https://t.co/ub0CGRs0fy Multimodal Tx is safe in select pts >80 with locally adv eso ca! Don't let age put you off! @LFerri123 @sara_najmeh @JonathanCools @DoctorJSpicer🚨🚨🚨 (@JamieTankel)

#ClinicalTrial EA2183, led by @NataliyaUboha of @UWHealth, is testing the addition of #radiotherapy to chemotherapy for patients w/ #esophageal and #GastricCancer. For more: https://t.co/YDD5pHUqPv #StomachCancer #GICSM #esocsm (@eaonc)

Check out our recently published review—Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review https://t.co/WqPul1qpEM. @AliAlqahtaniMD @ChYin89 @caso_raul @mnoel3232 #pujakhaitan (@ReetuMukherjiMD)

Congratulations to @RichardPTEvans on passing his PhD viva on ‘Immunotherapeutic Opportunities in Oesophageal Adenocarcinoma’ today with Birmingham University @UoBSurgery @paulmos63832199 @news_ub @unibirm_MDS Thanks to @cstarlab and @LizzySmyth1 for coming to examine! (@EwenGriffiths)

Great discussion by @KoheiShitara and team of therapeutic biomarker results from LUD2015-005 (mostly EAC) and JUPITER-06 (ESCC), and potential future directions: https://t.co/QxYT1c5UXq (@_tom_dot_com)

TODAY!! ENDOLUMINAL SURGERY FOR GI NEOPLASIA. Join @ScottRSteeleMD @jsommov @EmreGorgunMD @amitbhattMD @JohnVargoMD @OlgaLavryk @CleClinicMD CME event. Endo resection esophageal/gastric neoplasia/early CR neoplasia. Stenting GI malignancies. https://t.co/r8Uo5HXNdi (@RitaRys1)

EGFR Inhibition in EGFR–Amplified Gastroesophageal Cancer 60 pts ORR All pts➡️43% ChT plus EGFRi➡️57% mPFS All pts➡️4.6 mo ChT plus EGFRi➡️6.0 mo First line➡️6.9 mo 📌Well-selected patients with EGFR-amplified GEA derive significant benefit from EGFRi @JCO_ASCO… https://t.co/CJfrsAqzMH (@dr_yakupergun)

Check out this on demand webinar on gastroesophageal cancer provided by experts @YJanjigianMD @KlempnerSam and @LizzySmyth1 Now available as an accredited e-learning https://t.co/srAajgJZtN #MedEd (@giconnectInfo)

Newly diagnosed patients with Barrett esophagus have high rates of postendoscopy esophageal adenocarcinoma and postendoscopy esophageal neoplasia. Study in @AGA_Gastro. @KauppilaJoonas @nshaheenUNC #GItwitter #gastroenterology https://t.co/Ve9grXfO3G (@Gastro_Advisor)

Nearly half recur within a year and 90% is systemic recurrence despite treatment with curative intent confirms oesophageal cancer is a systemic disease! 1/2 (@venkarch)

https://t.co/widHfk1QfM 11% of patients have locoregional recurrence only after curative esophageal cancer treatment of whom a proportion can be treated with curative intent and have prolonged survival. Intensive surveillance may be beneficial in selected patients. @mivanbh (@SSGisbertz)

Thank you for your work. My brother Antonio Villa is having surgery today. He has cancer of the esophagus. Please keep him in your prayers and continue your essential work. God bless you. 🙏🙏🙏🙏🙏 (@kassi_ydris)

Out in @CCR_AACR. @SteveMaronMD @ILSONDavid @JeeyunM @YJanjigianMD and others. Determinants of survival in HER2+ metastatic esophagogastric cancer https://t.co/1JnQbb0krS (@KlempnerSam)

S1 +RT for elderly SCC esophagus. Question is many patients have Ryles tube and can S1 be crushed and delivered? @VikramGota @VanitaNoronha @Anil_Tibdewal @naveenmummudi1 @indranilsays https://t.co/KYNF6uUChI (@DrVijayPatil11)

Research exploring #predictive effects of two common genes associated with Tertiary Lymphoid Structures models on #prognosis and #immunotherapy effects in Esophageal squamous cell carcinoma patients 🔗https://t.co/fe5for4JiZ @DraMartinezLago @KEN_K_ @ISDE_net #GITwitter (@TumoriJ)

#ClinicalTrial EA2183, led by @NataliyaUboha of @UWHealth, is testing the addition of #radiotherapy to chemotherapy for patients w/ #esophageal and #GastricCancer. For more: https://t.co/YDD5pHTSZX #StomachCancer #GICSM #esocsm (@eaonc)

Optimal use of systemic agents clearly key to managing systemic failures with definitive chemoradiotherapy and there has been some positive data in the neoadjuvant setting for PET-directed chemo switch in patients with oesophageal adenocarcinomas (CALGB80803 @KarynAGoodman). (@DrCMJones)

Tune in July 12 ENDOLUMINAL SURGERY FOR GI NEOPLASIA. Join @ScottRSteeleMD @jsommov @EmreGorgunMD @amitbhattMD @JohnVargoMD @OlgaLavryk @CleClinicMD CME event. Endo resection esophageal/gastric neoplasia/early CR neoplasia. Stenting GI malignancies. https://t.co/r8Uo5HXNdi (@RitaRys1)

📣 Dr. John L. Marhsall (@marshalj23) explains how to incorporate into practice the latest data on #HER2-positive gastric/gastroesophageal junction #cancers ✅ Updating healthcare professionals' know-how in the use of data is key for the benefit of #patients (@FundacionECO)

Biggest yes I have ever said. Super excited to accept a PhD at @dundeeuni. Looking forward to the start of something amazing. Together we will continue to improve outcomes for patients with oesophageal cancer @HeartburnCancer @SouthamptonCTU @RussellPetty19 @TimTheSurgeon (@MissHClements)

Outstanding gastroesophageal cancer session at #WCGIC2023 and excellent abstract presentations from colleagues of our group 👏🏻@FilippoPietran4 @LizzySmyth1 @KoheiShitara #giovannirandon @Mom_enji (@margheambro1)

Checkpoint inhibition in ESCC by Markus Möhler at #WCGIC2023 @myESMO @WCGIC (@HosseinTaghiz11)

Fantastic talk by @FilippoPietran4 on MSI-H/dMMR esophagogastric cancers. I encourage everybody to rewatch! #WCGIC2023 @myESMO (@MyriamChalabi)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increased PDL-1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

#WCGIC2023 Neoadjuvant/Adjuvant IO therapy in gastric/GEJ/esophageal cancers. Nice discussion by Salah-Eddin Al-Batran. @myESMO #Barcellona More Questions than answers? (@HassanSheikh_MD)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increase in PDL1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

Congrats to @DrRonanKelly for a great presentation at #WCGIC2023 and moving the needle in understanding the role of adjuvant checkpoint inhibitor in esophageal and GEJ cancers! @ECAware @SalgiFoundation (@DrBonillaOnc)

Sugemalimab plus chemo vs placebo plus chemo in 1st line treatment of advanced esophageal carcinoma: ⬆️PFS (HR 0.57), ⬆️OS (HR 0.79) and ⬆️ORR (60.1% vs 45.2%). In subgroup analysis benefit was restricted to IHC PD-L1 CPS ≥ 10 #WCGIC2023 (@carlosbon78)

IMO 41.4 Gy is equal to 50.4 Gy in esophageal cancer. I think we should de-escalate rather than escalate. Nice thread from @KrishanJethwa (@RGhalehtaki)

Thanks again to @SprakerMDPhD @ParikhSimul @jaguaranna27 and the accelerators for hosting @yazshaz and I!! Check it out!! And… if you’re really bored 😂… here’s a little overview of definitive CRT dosing for esophagus cancer! https://t.co/aq9CAOEr1B (@KrishanJethwa)

This excellent discussion started by Dr. Sanford made me dig in to the TAP archives... Read this thread, then let @KrishanJethwa and @yazshaz round out your knowledge of #RadOnc for esophagus cancers! https://t.co/zsmbchHNa4 #MedEd @ARRO_org @ACROresident (@SprakerMDPhD)

do u mean that the 69 people found to have EAC within 365 days of an EGD diagnosing BE is a relatively low rate (69/20,588, 0.3%)? i read it as we miss at least 1/4 of esophageal cancers at index egd dx’ing BE 😰so use a cap + nbi when evaluating 🥸 (@atjaved)

pCR rates drop in Extended CROSS trial. CROSS trial is only for early esophageal cancers. My post in a RT group from 11th May 2021. Also to remember 60 & 64 Gy failed to add any benefit, toxicity is a major concern. ILRT after EBRT adds little benefit. (@suryaoncology)